BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2894127)

  • 1. Adaptive changes in brain dopamine function as a result of neuroleptic treatment.
    Jenner P; Marsden CD
    Adv Neurol; 1988; 49():417-31. PubMed ID: 2894127
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic neuroleptic treatment and dopamine receptor regulation.
    Creese I; Snyder SH
    Adv Biochem Psychopharmacol; 1980; 24():89-94. PubMed ID: 6105809
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
    Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
    J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of chronic neuroleptic administration on cerebral dopamine receptor function.
    Rupniak MN; Jenner P; Marsden CD
    Life Sci; 1983 May; 32(20):2289-311. PubMed ID: 6133203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status of our knowledge of the neurotropic side effects of neuroleptic drugs].
    Sabbatini F; Pinessi L; Gentile S; De Mattei M; Portaleone P
    Minerva Psichiatr; 1983; 24(4):145-53. PubMed ID: 6145083
    [No Abstract]   [Full Text] [Related]  

  • 10. Tardive dyskinesia: a biological appraoch.
    Barbaccia ML; Trabucchi M
    Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
    [No Abstract]   [Full Text] [Related]  

  • 11. [Current theories on the role of dopamine in the mechanism of action of neuroleptic drugs].
    Płaźnik A; Kostowski W
    Psychiatr Pol; 1984; 18(1):39-47. PubMed ID: 6146150
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
    Jenner P; Kerwin R; Rupniak NM; Murugaiah K; Hall MD; Fleminger S; Marsden CD
    J Neural Transm Suppl; 1983; 18():205-12. PubMed ID: 6135741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced movement disorders.
    Gershanik OS
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):369-76. PubMed ID: 8099509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
    Spano PF; Memo M; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.
    Scatton B
    J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430
    [No Abstract]   [Full Text] [Related]  

  • 16. Binding of a conformationally restricted dopamine analogue, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, to receptors on rat brain synaptic membranes.
    Roberts PJ; Woodruff GN; Poat JA
    Mol Pharmacol; 1977 May; 13(3):541-7. PubMed ID: 17829
    [No Abstract]   [Full Text] [Related]  

  • 17. Mesolimbic system and tardive dyskinesia: new perspectives for therapy.
    Cools AR
    Mod Probl Pharmacopsychiatry; 1983; 21():111-23. PubMed ID: 6140628
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidemiology and pathophysiology of tardive dyskinesias.
    Klawans HL; Tanner CM; Goetz CG
    Adv Neurol; 1988; 49():185-97. PubMed ID: 2894124
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neuroleptics and nicotine].
    Erdmann R
    Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiologic basis of tardive dyskinesia.
    Baldessarini RJ
    Psychopharmacol Bull; 1978 Oct; 14(4):79-81. PubMed ID: 30114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.